KINASE INHIBITORS
Early Diagnosis, Clinical Management, and Follow-up of Cardiovascular Events with Ponatinib
Italian researchers present a review of the most recent evidence of cardiovascular events associated with the use of third-generation tyrosine kinase inhibitor ponatinib, as well as the most beneficial feasible diagnosis and follow-up methods.
Heart Failure Reviews
